{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:50:19Z","timestamp":1792788619009,"version":"4.5.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"KUROKAWA CANCER RESEARCH FOUNDATION","award":["Grant-in-Aid"],"award-info":[{"award-number":["Grant-in-Aid"]}],"id":[{"id":"https:\/\/ror.org\/052nngb38","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Staging laparoscopy (SL) is a minimally invasive approach for detecting occult metastases in patients with pancreatic cancer (PC) without signs of metastasis on imaging. This study aimed to identify the predictive factors for imaging-negative occult metastases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective study enrolled 199 patients with histologically confirmed PC from three institutions between August 2021 and April 2023. All patients were scheduled for a treatment plan that included SL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The overall metastasis rate as detected using SL was 25.1%, which varied from 20.6% in patients with resectable PC (R-PC) to 33.8% in those with borderline resectable or locally advanced unresectable PC (BR\/URLA-PC). In 152 patients who did not receive neoadjuvant therapy, BR\/URLA status (odds ratio 3.261; 95% confidence interval 1.185\u20139.483,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.022) and pancreatic body\/tail lesions (odds ratio 2.653; 95% confidence interval 1.037\u20137.214,\n                      <jats:italic>p\u2009<\/jats:italic>\n                      =\u20090.042) were independent risk factors for occult metastatic lesions (M1). Among the 107 patients with R-PC, M1 disease was significantly associated with pancreatic body\/tail lesions, tumor size, and elevated levels of tumor markers. In particular, elevated carbohydrate antigen 19-9 levels were consistent across all patients with M1 pancreatic head cancer. In contrast, no statistical differences were observed for any of these factors in the 45 patients with BR\/URLA-PC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings support the importance of SL in patients with BR\/UR PC. For R-PC, patients with pancreatic head lesions and normal tumor marker values may represent a very low-risk subgroup where selective omission of SL can be considered in resource-constrained settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-20728-8","type":"journal-article","created":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:58:59Z","timestamp":1791925139000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive Factors for Occult Metastases in Clinically M0 Pancreatic Cancer: A Prospective Multicenter Analysis of Staging Laparoscopy"],"prefix":"10.1245","author":[{"given":"Masahiro","family":"Iseki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Igarashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamichi","family":"Mizuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Ariake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shimpei","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Shibuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaku","family":"Yoshioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhisa","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuyuhiko","family":"Motoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiaki","family":"Unno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,13]]},"reference":[{"issue":"1","key":"20728_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"20728_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1097\/SLA.0000000000006730","volume":"283","author":"M Unno","year":"2026","unstructured":"Unno M, Motoi F, Matsuyama Y, et al. Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer: results of the randomized phase II\/III Prep-02\/JSAP05 trial. Ann Surg. 2026;283(1):57\u201364. https:\/\/doi.org\/10.1097\/SLA.0000000000006730.","journal-title":"Ann Surg."},{"key":"20728_CR3","doi-asserted-by":"publisher","unstructured":"Ishida M, Fujii T, Kishiwada M, et al. Japanese classification of pancreatic carcinoma by the Japan Pancreas Society Eighth edition. J Hepatobiliary Pancreat Sci. 2024;31(11):755-768. https:\/\/doi.org\/10.1002\/jhbp.12056","DOI":"10.1002\/jhbp.12056"},{"issue":"19","key":"20728_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364(19):1817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1011923.","journal-title":"N Engl J Med."},{"issue":"6","key":"20728_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","volume":"17","author":"SB Edge","year":"2010","unstructured":"Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17(6):1471\u20134. https:\/\/doi.org\/10.1245\/s10434-010-0985-4.","journal-title":"Ann Surg Oncol."},{"issue":"18","key":"20728_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703. https:\/\/doi.org\/10.1056\/NEJMoa1304369.","journal-title":"N Engl J Med."},{"issue":"3","key":"20728_CR7","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1046\/j.1365-2168.2001.01695.x","volume":"88","author":"PW Pisters","year":"2001","unstructured":"Pisters PW, Lee JE, Vauthey JN, Charnsangavej C, Evans DB. Laparoscopy in the staging of pancreatic cancer. Br J Surg. 2001;88(3):325\u201337. https:\/\/doi.org\/10.1046\/j.1365-2168.2001.01695.x.","journal-title":"Br J Surg."},{"issue":"12","key":"20728_CR8","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1002\/jhbp.408","volume":"23","author":"I Karabicak","year":"2016","unstructured":"Karabicak I, Satoi S, Yanagimoto H, et al. Risk factors for latent distant organ metastasis detected by staging laparoscopy in patients with radiologically defined locally advanced pancreatic ductal adenocarcinoma. J Hepatobiliary Pancreat Sci. 2016;23(12):750\u20135. https:\/\/doi.org\/10.1002\/jhbp.408.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"1","key":"20728_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s1072-7515(99)00075-7","volume":"189","author":"SF Sener","year":"1999","unstructured":"Sener SF, Fremgen A, Menck HR, Winchester DP. Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985\u20131995, using the National Cancer Database. J Am Coll Surg. 1999;189(1):1\u20137. https:\/\/doi.org\/10.1016\/s1072-7515(99)00075-7.","journal-title":"J Am Coll Surg."},{"issue":"2","key":"20728_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1093\/annonc\/mdj013","volume":"17","author":"D Stefanidis","year":"2006","unstructured":"Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr. The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol. 2006;17(2):189\u201399. https:\/\/doi.org\/10.1093\/annonc\/mdj013.","journal-title":"Ann Oncol."},{"issue":"7","key":"20728_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/jhbp.1436","volume":"31","author":"T Yoshimura","year":"2024","unstructured":"Yoshimura T, Shimizu A, Kitahata Y, et al. Scoring system to predict positive peritoneal cytology in patients with resectable and borderline resectable pancreatic cancer. J Hepatobiliary Pancreat Sci. 2024;31(7):492\u2013502. https:\/\/doi.org\/10.1002\/jhbp.1436.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"11","key":"20728_CR12","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1002\/jhbp.1356","volume":"30","author":"M Fukasawa","year":"2023","unstructured":"Fukasawa M, Watanabe T, Tanaka H, et al. Efficacy of staging laparoscopy for resectable pancreatic cancer on imaging and the therapeutic effect of systemic chemotherapy for positive peritoneal cytology. J Hepatobiliary Pancreat Sci. 2023;30(11):1261\u201372. https:\/\/doi.org\/10.1002\/jhbp.1356.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"1","key":"20728_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/jhbp.12074","volume":"32","author":"K Ariake","year":"2025","unstructured":"Ariake K, Mizuma M, Unno M, et al. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: a nationwide multicenter retrospective cohort study supervised by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. J Hepatobiliary Pancreat Sci. 2025;32(1):69\u201381. https:\/\/doi.org\/10.1002\/jhbp.12074.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"11","key":"20728_CR14","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/jhbp.1373","volume":"30","author":"N Tanaka","year":"2023","unstructured":"Tanaka N, Takami H, Hayashi M, et al. Predictive impacts of peritoneal washing cytology for surgical resection-intended pancreatic cancer cases: establishment of planned staging laparoscopy criteria. J Hepatobiliary Pancreat Sci. 2023;30(11):1273\u201381. https:\/\/doi.org\/10.1002\/jhbp.1373.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"1","key":"20728_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12957-016-0767-y","volume":"14","author":"S Satoi","year":"2016","unstructured":"Satoi S, Yanagimoto H, Yamamoto T, et al. A clinical role of staging laparoscopy in patients with radiographically defined locally advanced pancreatic ductal adenocarcinoma. World J Surg Oncol. 2016;14(1):14. https:\/\/doi.org\/10.1186\/s12957-016-0767-y.","journal-title":"World J Surg Oncol."},{"issue":"4","key":"20728_CR16","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1245\/s10434-017-6317-1","volume":"25","author":"NM Sell","year":"2018","unstructured":"Sell NM, Fong ZV, Del Castillo CF, et al. Staging laparoscopy not only saves patients an incision, but may also help them live longer. Ann Surg Oncol. 2018;25(4):1009\u201316. https:\/\/doi.org\/10.1245\/s10434-017-6317-1.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20728_CR17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000488372","volume":"36","author":"R Ta","year":"2019","unstructured":"Ta R, O\u2019Connor DB, Sulistijo A, Chung B, Conlon KC. The role of staging laparoscopy in resectable and borderline resectable pancreatic cancer: a systematic review and meta-analysis. Dig Surg. 2019;36(3):251\u201360. https:\/\/doi.org\/10.1159\/000488372.","journal-title":"Dig Surg."},{"issue":"5","key":"20728_CR18","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s00595-020-02121-4","volume":"51","author":"T Takadate","year":"2021","unstructured":"Takadate T, Morikawa T, Ishida M, et al. Staging laparoscopy is mandatory for the treatment of pancreatic cancer to avoid missing radiologically negative metastases. Surg Today. 2021;51(5):686\u201394. https:\/\/doi.org\/10.1007\/s00595-020-02121-4.","journal-title":"Surg Today."},{"issue":"2","key":"20728_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/00000658-199602000-00004","volume":"223","author":"KC Conlon","year":"1996","unstructured":"Conlon KC, Dougherty E, Klimstra DS, Coit DG, Turnbull AD, Brennan MF. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg. 1996;223(2):134\u201340. https:\/\/doi.org\/10.1097\/00000658-199602000-00004.","journal-title":"Ann Surg."},{"issue":"1","key":"20728_CR20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/ags3.12719","volume":"8","author":"T Igarashi","year":"2024","unstructured":"Igarashi T, Fukasawa M, Watanabe T, et al. Evaluating staging laparoscopy indications for pancreatic cancer based on resectability classification and treatment strategies for patients with positive peritoneal washing cytology. Ann Gastroenterol Surg. 2024;8(1):124\u201332. https:\/\/doi.org\/10.1002\/ags3.12719.","journal-title":"Ann Gastroenterol Surg."},{"issue":"1","key":"20728_CR21","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/XCS.0000000000000704","volume":"237","author":"H Gudmundsdottir","year":"2023","unstructured":"Gudmundsdottir H, Yonkus JA, Alva-Ruiz R, et al. Yield of staging laparoscopy for pancreatic cancer in the modern era: analysis of more than 1,000 consecutive patients. J Am Coll Surg. 2023;237(1):49\u201357. https:\/\/doi.org\/10.1097\/XCS.0000000000000704.","journal-title":"J Am Coll Surg."},{"issue":"7","key":"20728_CR22","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1245\/s10434-024-15221-z","volume":"31","author":"T Sumiyoshi","year":"2024","unstructured":"Sumiyoshi T, Uemura K, Shintakuya R, et al. Clinical utility of the combined use of CA19-9 and DUPAN-2 in pancreatic adenocarcinoma. Ann Surg Oncol. 2024;31(7):4665\u201372. https:\/\/doi.org\/10.1245\/s10434-024-15221-z.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"20728_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant. 2013;48(3):452\u20138. https:\/\/doi.org\/10.1038\/bmt.2012.244.","journal-title":"Bone Marrow Transplant."},{"issue":"14","key":"20728_CR24","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473\u201381. https:\/\/doi.org\/10.1001\/jama.2013.279201.","journal-title":"JAMA."},{"issue":"6","key":"20728_CR25","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.21873\/invivo.13380","volume":"37","author":"Y Shindo","year":"2023","unstructured":"Shindo Y, Tokumitsu Y, Matsui H, et al. Efficacy of staging laparoscopy in patients with pancreatic cancer: a single center prospective cohort study. In Vivo. 2023;37(6):2704\u20139. https:\/\/doi.org\/10.21873\/invivo.13380.","journal-title":"In Vivo."},{"issue":"1","key":"20728_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s11605-014-2637-7","volume":"19","author":"S Satoi","year":"2015","unstructured":"Satoi S, Murakami Y, Motoi F, et al. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. J Gastrointest Surg. 2015;19(1):6\u201314. https:\/\/doi.org\/10.1007\/s11605-014-2637-7.","journal-title":"J Gastrointest Surg."},{"issue":"6","key":"20728_CR27","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/jso.24402","volume":"114","author":"W Steen","year":"2016","unstructured":"Steen W, Blom R, Busch O, et al. Prognostic value of occult tumor cells obtained by peritoneal lavage in patients with resectable pancreatic cancer and no ascites: a systematic review. J Surg Oncol. 2016;114(6):743\u201351. https:\/\/doi.org\/10.1002\/jso.24402.","journal-title":"J Surg Oncol."},{"issue":"6","key":"20728_CR28","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.surg.2019.06.023","volume":"166","author":"H Tsuchida","year":"2019","unstructured":"Tsuchida H, Fujii T, Mizuma M, et al. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: a nationwide, cancer registry-based study from the Japan Pancreas Society. Surgery. 2019;166(6):997\u20131003. https:\/\/doi.org\/10.1016\/j.surg.2019.06.023.","journal-title":"Surgery."},{"issue":"9","key":"20728_CR29","doi-asserted-by":"publisher","first-page":"15004","DOI":"10.18632\/oncotarget.14745","volume":"8","author":"F Cao","year":"2017","unstructured":"Cao F, Li J, Li A, Li F. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: a systemic review and meta-analysis. Oncotarget. 2017;8(9):15004\u201313. https:\/\/doi.org\/10.18632\/oncotarget.14745.","journal-title":"Oncotarget."},{"issue":"8","key":"20728_CR30","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.pan.2020.08.022","volume":"20","author":"S Aoki","year":"2020","unstructured":"Aoki S, Mizuma M, Hayashi H, et al. Prognostic impact of intraoperative peritoneal cytology after neoadjuvant therapy for potentially resectable pancreatic cancer. Pancreatology. 2020;20(8):1711\u20137. https:\/\/doi.org\/10.1016\/j.pan.2020.08.022.","journal-title":"Pancreatology."},{"issue":"5","key":"20728_CR31","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.pan.2022.04.004","volume":"22","author":"H Otsuka","year":"2022","unstructured":"Otsuka H, Uemura K, Kondo N, et al. Preoperative risk factors for positivity of peritoneal lavage cytology in patients with pancreatic ductal adenocarcinoma in the era of neoadjuvant therapy. Pancreatology. 2022;22(5):583\u20139. https:\/\/doi.org\/10.1016\/j.pan.2022.04.004.","journal-title":"Pancreatology."},{"issue":"16","key":"20728_CR32","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763\u201373. https:\/\/doi.org\/10.1200\/JCO.19.02274.","journal-title":"J Clin Oncol."},{"issue":"11","key":"20728_CR33","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1200\/JCO.21.02233","volume":"40","author":"E Versteijne","year":"2022","unstructured":"Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220\u201330. https:\/\/doi.org\/10.1200\/JCO.21.02233.","journal-title":"J Clin Oncol."},{"issue":"2","key":"20728_CR34","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/jjco\/hyy190","volume":"49","author":"F Motoi","year":"2019","unstructured":"Motoi F, Kosuge T, Ueno H, et al. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05). Jpn J Clin Oncol. 2019;49(2):190\u20134. https:\/\/doi.org\/10.1093\/jjco\/hyy190.","journal-title":"Jpn J Clin Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-20728-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-20728-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:49:01Z","timestamp":1791949741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-20728-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,13]]},"references-count":34,"alternative-id":["20728"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-20728-8","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,13]]},"assertion":[{"value":"2 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Unno received honoraria from MSD, AstraZeneca, and Taiho Pharmaceutical. The other authors have no relevant conflicts of interest to disclose.","order":1,"name":"Ethics","label":"Disclosure","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional review board of Tohoku University Graduate School of Medicine (no. 2021-1-314), University of Toyama (no. R2021153), and Yamagata University (no. 2021-235) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study before enrollment.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Ethics"}}]}}